Delayed cytogenetic response with prolonged interferon-α treatment in chronic myeloid leukemia patients: Quantification of BCR-ABL transcript by competitive reverse transcription-polymerase chain reaction

Haematologica

Volumn 86, Issue 10, 2001, Pages 1101-1103

  Perego, R A ^a   Nosari, A M ^a   Cornacchini, G ^a   Bianchi, C ^a   Corizzato, M ^a   Morra, E ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

BCR ABL transcript; Chronic myelogenous leukemia; Competitive RT PCR; Cytogenetics; Interferon

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN;

ADULT; AGED; ARTICLE; BLAST CELL CRISIS; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; DOSE RESPONSE; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; METAPHASE; MOLECULAR CLONING; PHILADELPHIA 1 CHROMOSOME; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION;

ADULT; AGED; CYTOGENETIC ANALYSIS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 0034757495     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Interferon α-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia
2. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. The Leukemia Service
3. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation
4. Quantitative PCR techniques and application
5. Detection by polymerase chain reaction of BCR/ABL transcripts in myeloproliferative diseases at time of diagnosis and for monitoring chronic myelogenous leukaemia patients after bone marrow transplantation
6. Prognostic discrimination in "good-risk" chronic granulocytic leukemia
7. Low doses of interferon-α are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia
8. An extremely delayed cytogenetic response to interferon-α in a patient with chronic myeloid leukaemia
9. Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-α therapy or allogenic bone marrow transplantation
10. Molecular heterogeneity in complete cytogenetic responders after interfer- on-α therapy for chronic myelogenous leukemia: Low levels of minimal residual disease are associated with continuing remission